{
  "id": "cluster_5_doc6",
  "content": "Research note from Crestview Medical Center indicates that 68% of patients on policy HNX-882K receiving IL-2 therapy required treatment modifications within first three cycles. Secondary analysis shows improved tolerance in patients transitioning to interferon-alpha regimens as per study ONC-2023-441 protocols.",
  "metadata": {
    "format": "research_note"
  }
}